Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use (NCT06379984)
Rapid Outpatient Low-dose Initiation of Buprenorphine for Individuals With OUD Using Fentanyl
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test. Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpatient low-dose initiation (ROLDI). For standard initiation, participants will be instructed to arrive to the unit with at least 8 hours since last fentanyl use. Once they have at least moderately severe opioid withdrawal (Clinical Opiate Withdrawal Scale \[COWS\] 11 or higher), participants will receive 2 mg, 2 mg, 4 mg, and then 8 mg sublingual buprenorphine, with doses every 2 hours. They will then continue 8 mg twice daily (or up to three times daily). This is the current standard of care. For ROLDI, participants will not be required to have a period abstinence, they will have no or minimal withdrawal (COWS 4 or less) when starting buprenorphine, and participants will take 0.5, 0.5, 0.5, 0.5, 2, 16 mg with doses scheduled every 2 hours. They will then continue 8mg twice daily (or up to three times daily). The main aim of this clinical trial is to assess whether ROLDI is safe, feasible, acceptable to patients, and worthwhile to study in a larger trial. The secondary aim is to describe fentanyl and norfentanyl pharmacokinetics (that is to say, fentanyl and norfentanyl concentration in blood and urine) during early abstinence to understand why some people using fentanyl develop precipitated withdrawal with standard initiation.
Who can join: Review the eligibility criteria below.
Location: University of Pennsylvania Center for Studies of Addiction — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Pennsylvania Center for Studies of Addiction — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 746-2764
Email: kampman@pennmedicine.upenn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Opioid Use Disorder
- Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Atlantic City, New Jersey
- The Emergency Department Longitudinal Integrated Care — Seattle, Washington
- Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT — La Jolla, California
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy — Boston, Massachusetts
- Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial — Ann Arbor, Michigan
- Telemedicine XR-B for Individuals in Jail — Cumberland, Maryland
Explore by condition: All Opioid Use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.